Key result
Single or multiple thrombophilic defects were not associated with a higher risk of recurrent VTE during warfarin therapy compared to no defects (HR for one defect 0.7; 95% CI 0.2-2.3).
Why the study?
Does the presence of thrombophilia increase the risk of recurrent venous thromboembolism in patients with unprovoked VTE on warfarin therapy?
Population
661 patients with unprovoked venous thromboembolism (VTE)
Comparison
Presence of single or multiple thrombophilic… vs Absence of thrombophilic defects
Design
RCT, Randomized to extended low-intensity or conventional-intensity…
Follow-up
mean 2.3 years
Authors
Loading...
Thrombophilia status should not alter warfarin management in unprovoked VTE; challenges its role in recurrence risk stratification during anticoagulation.
RCT (n=661)
Extended low-intensity vs conventional-intensity
Does the presence of thrombophilia increase the risk of recurrent venous thromboembolism in patients with unprovoked VTE on warfarin therapy?
Effect estimate: HR 0.7 (95% CI 0.2-2.3)
The presence of single or multiple thrombophilic defects does not increase the risk of recurrent VTE in patients receiving warfarin therapy for unprovoked VTE.
Kearon et al. (2008) conducted an RCT in Unprovoked VTE (n=661). Thrombophilia (one defect) vs. No thrombophilic defects was evaluated on Recurrent venous thromboembolism (HR 0.7, 95% CI 0.2-2.3). Single or multiple thrombophilic defects were not associated with a higher risk of recurrent VTE during warfarin therapy compared to no defects (HR for one defect 0.7; 95% CI 0.2-2.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: